靶向α发射体212Pb-DOTAMTATE治疗转移性表达生长抑素受体的神经内分泌肿瘤:首次人体剂量递增临床试验
这项首次人体1期剂量递增试验评估了靶向α发射体212Pb-DOTAMTATE在生长抑素受体阳性神经内分泌肿瘤患者中的安全性和初步疗效。20例受试者中,接受推荐2期剂量(每8周静脉给药2.50 MBq/kg,共4周期)的前10例患者客观影像学缓解率为80%。治疗耐受性良好,常见不良事件为恶心、乏力和脱发,无与研究药物相关的严重不良事件。
要点
- 推荐2期剂量为每8周静脉给予2.50 MBq/kg的212Pb-DOTAMTATE,共4个周期。
- 接受推荐2期剂量的前10例患者客观影像学缓解率为80%。
- 治疗耐受性良好,无研究药物相关严重不良事件,无患者需延迟治疗或减量。
核心结论
- 靶向α治疗212Pb-DOTAMTATE耐受性良好,初步疗效结果高度有前景。
- 若这些结果在更大规模的多中心临床试验中得到证实,212Pb-DOTAMTATE将为转移性或不可手术的表达SSTR的神经内分泌肿瘤患者提供优于目前FDA批准疗法的实质性获益, regardless of the grade and location of the primary tumor。
研究设计与样本
- 这是一项1期首次人体剂量递增临床试验,评估212Pb-DOTAMTATE(双功能金属螯合剂DOTAM与SSTR靶向肽TATE)在生长抑素受体阳性神经内分泌肿瘤患者中的表现。
- 入组20例组织学确诊的神经内分泌肿瘤受试者,均有既往阳性生长抑素类似物扫描结果,无既往177Lu/90Y/111In肽受体放疗史,原发部位不同。
- 治疗先从单次递增剂量开始,后续队列剂量递增30%,持续至观察到肿瘤缓解或剂量限制性毒性,随后进行多次递增剂量方案。
- 推荐2期剂量方案为每8周静脉给予2.50 MBq/kg(67.6 μCi/kg)的212Pb-DOTAMTATE,共4个周期。
主要发现
- 10例受试者接受了最高剂量2.50 MBq/kg/周期(67.6 μCi/kg/周期)。
- 治疗耐受性良好,最常见治疗中出现的不良事件为恶心、乏力和脱发。
- 无与研究药物相关的严重治疗中出现的不良事件,无受试者需要延迟治疗或减量。
- 接受推荐2期剂量治疗的前10例受试者中观察到80%的客观影像学缓解率。
关键数值与推荐
- 推荐2期剂量为2.50 MBq/kg(67.6 μCi/kg)的212Pb-DOTAMTATE,每8周静脉给药,共4个周期。
- 接受推荐2期剂量的前10例受试者客观影像学缓解率为80%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peptide receptor radiotherapy with somatostatin analogs has been successfully used for years as a treatment for somatostatin-overexpressing tumors. Treatment of neuroendocrine tumors (NETs) with the β-particle emitter 177Lu-DOTATATE is currently considered the standard of care for subjects with gastroenteropancreatic NETs. Despite the success of 177Lu-DOTATATE, there remains significant room for improvement in terms of both safety and efficacy. Targeted α-emitter therapy with isotopes such as 212Pb has the potential to improve both. Here, we present the preliminary results of the phase 1 first-in-humans dose-escalation trial evaluating 212Pb-DOTAMTATE (a bifunctional metal chelator [DOTAM] and the SSTR-targeting peptide [TATE]) in patients with somatostatin receptor-positive NETs. Methods: Twenty subjects with histologically confirmed NETs, prior positive somatostatin analog scans, and no prior history of 177Lu/90Y/111In peptide receptor radiotherapy, with different primary sites of the disease, were enrolled. Treatment began with single ascending doses of 212Pb-DOTAMTATE, with subsequent cohorts receiving an incremental 30% dose increase, which was continued until a tumor response or a dose-limiting toxicity was observed. This was followed by a multiple ascending dose regimen. The recommended phase 2 dose regimen consisted of 4 cycles of 2.50 MBq/kg (67.6 μCi/kg) of 212Pb-DOTAMTATE administered at 8-wk intervals, intravenously. Results: Ten subjects received the highest dose, 2.50 MBq/kg/cycle (67.6 μCi/kg/cycle). Treatment was well tolerated, with the most common treatment-emergent adverse events being nausea, fatigue, and alopecia. No serious treatment-emergent adverse events were related to the study drug, and no subjects required treatment delay or a dose reduction. An objective radiologic response of 80% was observed for the first 10 subjects treated at the recommended phase 2 dose. Conclusion: Targeted α-therapy with 212Pb-DOTAMTATE has been shown to be well tolerated. Preliminary efficacy results are highly promising. If these results are confirmed in a larger, multicenter clinical trial, 212Pb-DOTAMTATE would provide a substantial benefit over currently Food and Drug Administration-approved therapies for patients with metastatic or inoperable SSTR-expressing NETs regardless of the grade and location of the primary tumor.
引用
- Delpassand ES, Tworowska I, Esfandiari R, et al. Targeted α-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial. J Nucl Med. 2022. PMID: 34992153. doi:10.2967/jnumed.121.263230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。